FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2176136391> ?p ?o ?g. }

• W2176136391 endingPage "127" @default.
• W2176136391 startingPage "127" @default.
• W2176136391 abstract "Comparisons of the relative effect of 3 anti-vascular endothelial growth factor agents to treat diabetic macular edema warrant further assessment.To provide additional outcomes from a randomized trial evaluating 3 anti-vascular endothelial growth factor agents for diabetic macular edema within subgroups based on baseline visual acuity (VA) and central subfield thickness (CST) as evaluated on optical coherence tomography.Post hoc exploratory analyses were conducted of randomized trial data on 660 adults with diabetic macular edema and decreased VA (Snellen equivalent, approximately 20/32 to 20/320). The original study was conducted between August 22, 2012, and August 28, 2013. Analysis was conducted from January 7 to June 2, 2015.Repeated 0.05-mL intravitreous injections of 2.0 mg of aflibercept (224 eyes), 1.25 mg of bevacizumab (218 eyes), or 0.3 mg of ranibizumab (218 eyes) as needed per protocol.One-year VA and CST outcomes within prespecified subgroups based on both baseline VA and CST thresholds, defined as worse (20/50 or worse) or better (20/32 to 20/40) VA and thicker (≥400 µm) or thinner (250 to 399 µm) CST.In the subgroup with worse baseline VA (n = 305), irrespective of baseline CST, aflibercept showed greater improvement than bevacizumab or ranibizumab for several VA outcomes. In the subgroup with better VA and thinner CST at baseline (61-73 eyes across 3 treatment groups), VA outcomes showed little difference between groups; mean change was +7.2, +8.4, and +7.6 letters in the aflibercept, bevacizumab, and ranibizumab groups, respectively. However, in the subgroup with better VA and thicker CST at baseline (31-43 eyes), there was a suggestion of worse VA outcomes in the bevacizumab group; mean change from baseline to 1 year was +9.5, +5.4, and +9.5 letters in the aflibercept, bevacizumab, and ranibizumab groups, respectively, and VA letter score was greater than 84 (approximately 20/20) in 21 of 33 (64%), 7 of 31 (23%), and 21 of 43 (49%) eyes, respectively. The adjusted differences and 95% CIs were 39% (17% to 60%) for aflibercept vs bevacizumab, 25% (5% to 46%) for ranibizumab vs bevacizumab, and 13% (-8% to 35%) for aflibercept vs ranibizumab.These post hoc secondary findings suggest that for eyes with better initial VA and thicker CST, some VA outcomes may be worse in the bevacizumab group than in the aflibercept and ranibizumab groups. Given the exploratory nature of these analyses and the small sample size within subgroups, caution is suggested when using the data to guide treatment considerations for patients.clinicaltrials.gov Identifier: NCT01627249." @default.
• W2176136391 created "2016-06-24" @default.
• W2176136391 creator A5011697010 @default.
• W2176136391 creator A5015264417 @default.
• W2176136391 creator A5018888370 @default.
• W2176136391 creator A5021907714 @default.
• W2176136391 creator A5029688949 @default.
• W2176136391 creator A5039879095 @default.
• W2176136391 creator A5042011351 @default.
• W2176136391 creator A5042530127 @default.
• W2176136391 creator A5059376308 @default.
• W2176136391 creator A5061503632 @default.
• W2176136391 creator A5062651062 @default.
• W2176136391 creator A5067005074 @default.
• W2176136391 creator A5068302775 @default.
• W2176136391 creator A5081405643 @default.
• W2176136391 creator A5082592591 @default.
• W2176136391 creator A5083990113 @default.
• W2176136391 date "2016-02-01" @default.
• W2176136391 modified "2023-10-12" @default.
• W2176136391 title "Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema" @default.
• W2176136391 cites W1786299986 @default.
• W2176136391 cites W2083896509 @default.
• W2176136391 cites W2122668687 @default.
• W2176136391 cites W2137635384 @default.
• W2176136391 doi "https://doi.org/10.1001/jamaophthalmol.2015.4599" @default.
• W2176136391 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5567793" @default.
• W2176136391 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26605836" @default.
• W2176136391 hasPublicationYear "2016" @default.
• W2176136391 type Work @default.
• W2176136391 sameAs 2176136391 @default.
• W2176136391 citedByCount "61" @default.
• W2176136391 countsByYear W21761363912016 @default.
• W2176136391 countsByYear W21761363912017 @default.
• W2176136391 countsByYear W21761363912018 @default.
• W2176136391 countsByYear W21761363912019 @default.
• W2176136391 countsByYear W21761363912020 @default.
• W2176136391 countsByYear W21761363912021 @default.
• W2176136391 countsByYear W21761363912022 @default.
• W2176136391 countsByYear W21761363912023 @default.
• W2176136391 crossrefType "journal-article" @default.
• W2176136391 hasAuthorship W2176136391A5011697010 @default.
• W2176136391 hasAuthorship W2176136391A5015264417 @default.
• W2176136391 hasAuthorship W2176136391A5018888370 @default.
• W2176136391 hasAuthorship W2176136391A5021907714 @default.
• W2176136391 hasAuthorship W2176136391A5029688949 @default.
• W2176136391 hasAuthorship W2176136391A5039879095 @default.
• W2176136391 hasAuthorship W2176136391A5042011351 @default.
• W2176136391 hasAuthorship W2176136391A5042530127 @default.
• W2176136391 hasAuthorship W2176136391A5059376308 @default.
• W2176136391 hasAuthorship W2176136391A5061503632 @default.
• W2176136391 hasAuthorship W2176136391A5062651062 @default.
• W2176136391 hasAuthorship W2176136391A5067005074 @default.
• W2176136391 hasAuthorship W2176136391A5068302775 @default.
• W2176136391 hasAuthorship W2176136391A5081405643 @default.
• W2176136391 hasAuthorship W2176136391A5082592591 @default.
• W2176136391 hasAuthorship W2176136391A5083990113 @default.
• W2176136391 hasBestOaLocation W21761363911 @default.
• W2176136391 hasConcept C118487528 @default.
• W2176136391 hasConcept C126322002 @default.
• W2176136391 hasConcept C134018914 @default.
• W2176136391 hasConcept C141071460 @default.
• W2176136391 hasConcept C168563851 @default.
• W2176136391 hasConcept C2776403814 @default.
• W2176136391 hasConcept C2776694085 @default.
• W2176136391 hasConcept C2777802072 @default.
• W2176136391 hasConcept C2778257484 @default.
• W2176136391 hasConcept C2778749236 @default.
• W2176136391 hasConcept C2779829184 @default.
• W2176136391 hasConcept C2780347916 @default.
• W2176136391 hasConcept C2781100027 @default.
• W2176136391 hasConcept C2985127711 @default.
• W2176136391 hasConcept C555293320 @default.
• W2176136391 hasConcept C67761136 @default.
• W2176136391 hasConcept C71924100 @default.
• W2176136391 hasConceptScore W2176136391C118487528 @default.
• W2176136391 hasConceptScore W2176136391C126322002 @default.
• W2176136391 hasConceptScore W2176136391C134018914 @default.
• W2176136391 hasConceptScore W2176136391C141071460 @default.
• W2176136391 hasConceptScore W2176136391C168563851 @default.
• W2176136391 hasConceptScore W2176136391C2776403814 @default.
• W2176136391 hasConceptScore W2176136391C2776694085 @default.
• W2176136391 hasConceptScore W2176136391C2777802072 @default.
• W2176136391 hasConceptScore W2176136391C2778257484 @default.
• W2176136391 hasConceptScore W2176136391C2778749236 @default.
• W2176136391 hasConceptScore W2176136391C2779829184 @default.
• W2176136391 hasConceptScore W2176136391C2780347916 @default.
• W2176136391 hasConceptScore W2176136391C2781100027 @default.
• W2176136391 hasConceptScore W2176136391C2985127711 @default.
• W2176136391 hasConceptScore W2176136391C555293320 @default.
• W2176136391 hasConceptScore W2176136391C67761136 @default.
• W2176136391 hasConceptScore W2176136391C71924100 @default.
• W2176136391 hasIssue "2" @default.
• W2176136391 hasLocation W21761363911 @default.
• W2176136391 hasLocation W21761363912 @default.
• W2176136391 hasLocation W21761363913 @default.
• W2176136391 hasLocation W21761363914 @default.
• W2176136391 hasOpenAccess W2176136391 @default.

• next